<DOC>
	<DOCNO>NCT01266668</DOCNO>
	<brief_summary>The purpose study investigate impact rituximab primary breast DLBCL use match pair analysis follow strict match criterion patient primary breast nodal DLBCL treat rituximab plus cyclophosphamide , doxorubicin , vincristine , prednisone ( R-CHOP ) regimen .</brief_summary>
	<brief_title>The Impact Rituximab Patients With Primary Breast Diffuse Large B Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description>Primary breast lymphoma represent 1.7 % 2.2 % extranodal non-Hodgkin 's lymphoma . Histologically , diffuse large B cell lymphoma ( DLBCL ) predominant subtype PBL . Previous study pre-rituximab era identify bad outcome primary breast DLBCL compare nodal DLBCL . Few clinical study report investigate efficacy rituximab patient primary breast DLBCL . For clarify , large randomize trial compare survival patient primary breast DLBCL require . However , rarity primary breast DLBCL make large trial virtually difficult single center study group . Additionally , retrospective study evaluate role rituximab primary breast DLBCL bias accord difference treatment period CHOP R-CHOP era . Thus , attempt clarify impact rituximab survival pattern progression patient primary breast DLBCL , investigator perform matched pair analysis follow strict match criterion patient primary breast DLBCL , identify previous nation-wide survey , nodal DLBCL , select data registry Korean Society Hematology Lymphoma Working Party , treat R-CHOP regimen .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Stage I II primary breast DLBCL treat RCHOP Stage I II nodal DLBCL treat RCHOP Definition primary breast DLBCL Isolated breast involvement without nodal disease , include distant nodal disease well regional nodal disease Definition nodal DLBCL The disease limit lymph node lymphoid organ Primary breast DLBCL nodal DLBCL treat without rituximab Secondary breast DLBCL Recurrent DLBCL Stage III IV nodal DLBCL extranodal involvement dissemination process</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Diffuse large B cell lymphoma</keyword>
	<keyword>Breast</keyword>
	<keyword>Rituximab</keyword>
</DOC>